AngioSoma (OTC: SOAN) recently announced their intent to work with Biomedix to use PADnet for clinical research and trials, to evaluate the efficacy of their pharmaceutical intervention for PAD.
AngioSoma intends to use the PADnet device to select patients for clinical trials and determine the presence and severity of PAD in patients before and after using Liprostin™, its flagship patented pharmaceutical intervention for PAD.
“It’s a natural fit for us,” said Alex Blankenship, President of AngioSoma. “The ability to verify the effectiveness of treatment by testing before and after interventions will enhance our efficacy data, leading to greater visibility for our products going forward.”
